Detailed what your day would look like and resources provided to you. The interview process was more streamlined than I have experienced at other companies. The process took 4 weeks. See salaries, compare reviews, easily apply, and get hired. Flatiron Health No questions were asked other than the assessment Abstractors preferred the clinician-anchored approach as it ... and most practical, method for characterizing tumor-based endpoints from EHR-sourced data. Thought leaders discussed the current and future use of regulatory-grade real-world evidence. 8 Questions You Should Absolutely Ask An Interviewer. Keyboarding skills and experience with healthcare software is usually required. Applied online with resume and cover letter. What do you anticipate a workday to be like at your home should you be hired with Flatiron? The process took 3 weeks. Average salary: $65,454 There were three assessments: typing (1 min), basic computer skills (4 min), two cases scenarios (allowed 120 minutes). Find 18 questions and answers about working at Flatiron Health. I have 3+ years of cancer registry experience and excellent quality and still did not pass the case scenarios. I interviewed at Flatiron Health (United States). I called in and had a very nice casual/professional interview. Date agreement for those patients with at least one real-world progression event captured by two independent abstractors (n = 358) is displayed as a function of the date window (in days) applied. Accelerate research with the most advanced real-world evidence platform in oncology. 19 Flatiron Health reviews. They may also identify record deficiencies and enter results into a system. Flatiron is an impassioned startup, working towards great goals: to enable data to help cure cancer. You are tested on two subject areas and let go if you don't pass at least one test. Heard back with a coding assessment about a week after I applied. The process took 1+ week. In real life you would have support to ask questions. Senior Health Technology Assessment Research, Quantitative Sciences Full-Time, Flexible Schedule Job New York, NY Candidates need to be able to work in the City or State specified Flexible position will collaborate to help develop/execute strategy, help plan/execute collaboration with methods groups to advance applications, be the point of contact, and review of analytical strategy. The case scenarios were extremely difficult meaning if you have ACTUAL cancer registry experience you will realize that you have to go against what you've been taught and follow what they want you to do. Nurse Abstractor. Flatiron Health, Inc Remote Oncology Data Abstractor | Orlando, FL | August 2016 - Current. Received an email with a link to an assessment. There are over 172 data abstractor job careers waiting for you to apply! They need to re-evaluate the assessment because I'm not the only one. Real-world treatment patterns of maintenance therapy in platinum-sensitive recurrent epithelial ovarian cancer: are some patients missing out? I interviewed at Flatiron Health (New York, NY) in December 2016. They had conflicting information reported in a disorganized record and wanted you to answer the questions based on their rules but didn’t give adequate information to do so according to the rules. Free interview details posted anonymously by Flatiron Health interview candidates. I applied online. Flatiron Health Abstractor Interview Questions | Glassdoor. Nurse abstractors review patient files to abstract key data. I interviewed at Flatiron Health (New York, NY (US)) in January 2021. your local AHA Quality Improvement Director. I interviewed at Flatiron Health (New York, NY) in Dec 2020, First you had to completes typing and mock abstract assessment then was interviewed by individual. The process took 1 week. Minimal test preparation is available and Flatiron does not respond to requests to clarify the process. Learn how researchers are applying real-world data. The process took 2 weeks. How to Answer: What Are Your Strengths and Weaknesses? Hear Rick Pazdur's perspective. Learn how to enable cookies. Unlock the promise of your EHR data with Flatiron's enriched data infrastructure. 10 Flatiron Health Abstractor interview questions and 10 interview reviews. Copyright © 2008–2021, Glassdoor, Inc. "Glassdoor" and logo are registered trademarks of Glassdoor, Inc. I applied through an employee referral. Flatiron Health Abstraction Specialist Jobs, Flatiron Health Senior Manager, Product Operations Jobs, Flatiron Health Clinical Data Analyst Jobs, Flatiron Health Product Operations Associate Jobs, Flatiron Health Customer Support Associate Jobs, 9 Attention-Grabbing Cover Letter Examples, 10 of the Best Companies for Working From Home, The Top 20 Jobs With the Highest Satisfaction, 12 Companies That Will Pay You to Travel the World, 7 Types of Companies You Should Never Work For, How to Become the Candidate Recruiters Can’t Resist, 11 Words and Phrases to Use in Salary Negotiations, 10 High-Paying Jobs With Tons of Open Positions, Negotiating Over Email? Rates of systemic anticancer therapy (SACT) for advanced non-small cell lung cancer (aNSCLC) in the U.S. 2011-2018. Researchers, academics, oncologists, engineers and more all work together here to deliver better solutions. Flatiron Health provides a technology-enabled abstraction process to generate real-world evidence for cancer treatments. A free inside look at company reviews and salaries posted anonymously by employees. You are tested on two subject areas and let go if you don't pass at least one test. Flatiron’s former CMO & CSO, Amy Abernethy, and Dr. Rick Pazdur of the FDA discuss the agency’s engagement with real-world evidence, the path forward for RWE, and the future of cancer care at the 2018 Flatiron Research Summit. (#520), Real-world outcomes of patients with Diffuse Large B-Cell Lymphoma receiving second line therapy in the United States, Real-world IgG testing frequency and characteristics associated with hypogammaglobulinemia after anti-CD20 exposure in patients with chronic lymphocytic leukemia, Understanding the impact of assessment frequency on the study of adverse effects using oncology electronic health records, Deriving International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk categories using oncology electronic health records, Prospective validation of a clinical tool developed with machine learning to identify high-risk patients with cancer and reduce emergency department visits, Analytic considerations for constructing real-world comparator cohorts, Generalizable machine learning framework for predictive modeling of patient outcomes using oncology electronic health records, Validation analysis of a composite real-world mortality endpoint for US cancer patients, Identification of genomic alterations related to treatment progression in RWD, Association of baseline systemic corticosteroid use with time to next treatment in patients with advanced melanoma, non-small cell lung cancer or urothelial cancer receiving cancer immunotherapy in US clinical practice, Pan-cancer profiling of the effect of biopsied site on tumor mutational burden measurements in a real-world data cohort, Characterization and potential therapeutic implications of SMARCA4 variants revealed by targeted exome-sequencing of 131668 cancer patients, Characteristics and outcomes of real-world patients with microsatellite instability-high solid tumors treated with pembrolizumab monotherapy after FDA approval, Association of BRCA alteration type with real-world outcomes to PARP inhibitors in patients with metastatic castrate-resistant prostate cancer, An automated EHR-based tool for identification of patients with metastatic disease to facilitate clinical trial patient ascertainment, PD-L1 tumor proportion score and clinical benefit from first-line pembrolizumab in patients with advanced nonsquamous versus squamous non-small cell lung cancer, Use of real-world data to understand barriers to interventional clinical trial enrollment in community oncology clinics, A multi-stakeholder platform to prospectively link longitudinal real-world clinico-genomic, imaging, and outcomes data for patients with metastatic lung cancer, The adoption of immune checkpoint inhibitors and patterns of care at the end of life, Real-world outcomes for advanced non-small cell lung cancer patients with EGFR exon 19 deletions stratified by deletion size, Semi-automated discovery of real-world patient journeys from electronic health records: advanced non-small cell lung cancer, Impact of adherence to National Comprehensive Cancer Network-recommended first-line therapy on treatment duration for patients with advanced non-squamous non-small cell lung cancer, Utilization of next-generation sequencing and associated systemic therapy initiation in metastatic prostate cancer, Overall survival with docetaxel vs novel hormonal therapy with abiraterone or enzalutamide after a prior NHT in patients with metastatic prostate cancer: results from a real-world dataset, Real-world ALK testing compliance to NCCN guideline and factors of underutilization, Use of prophylactic cranial irradiation in patients with extensive-stage small cell lung cancer receiving immunotherapy, PD-1 targeted immunotherapy for advanced hepatocellular cancer: current utilization and outcomes in the United States, Real-world outcomes of patients with BRAF-mutated mCRC treated in the United States, Comparative effectiveness of second-line single-agent atezolizumab, nivolumab, and pembrolizumab in patients with locally advanced or metastatic urothelial cancer who progressed on platinum-based systemic chemotherapy: results from a real-world dataset, Real-world outcomes after second-line treatment in non-small cell lung cancer patients treated with immunotherapy, Prevalence of ALK mutation in advanced NSCLC patients in the United States, Uptake of targeted therapy in clinical practice among US patients with ovarian cancer, Patient characteristics and treatment patterns in relapsed/refractory multiple myeloma patients after exposure to a proteasome inhibitor, an immunomodulatory agent, and daratumumab, Racial disparities in utilization and effectiveness of first-line therapies in metastatic castrate-resistant prostate cancer, Trends in real-world clinical outcomes among patients with metastatic pancreatic adenocarcinoma treated with liposomal irinotecan based regimens in the United States, Genomic testing among patients with newly diagnosed advanced non-small cell lung cancer in the United States: a contemporary clinical practice patterns study, Role of real-world evidence for oncology product registration in the United States: a review of approvals by the U.S. Food and Drug Administration from 2015 to 2019, 12-month uptake of PD-L1 testing and atezolizumab + nab-paclitaxel treatment in metastatic triple-negative breast cancer following accelerated FDA-approval in the United States, Clinical outcomes between patients with and without RET fusions in advanced/metastatic non-small cell lung cancer in the United States, Indirect comparison of TAK-788 vs real-world data outcomes in refractory non-small cell lung cancer with EGFR exon 20 insertions, Real-world use of liposomal irinotecan-based regimens among patients with metastatic pancreatic adenocarcinoma in the United States, Real-world treatment patterns and clinical outcomes of advanced melanoma patients following disease progression on anti-PD-1-based therapy, Uptake of first-line immune checkpoint inhibitors among medically frail patients with advanced solid malignancies, Real-world dosing, management, and clinical outcomes of patients with metastatic pancreatic adenocarcinoma treated with liposomal irinotecan, Real-world outcomes among patients with epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors versus immunotherapy or chemotherapy in first-line setting. Please describe the problem with this {0} and we will look into it. Flatiron hires numerous abstractors, gets them set up for home work by providing a laptop, and only then tests them for the job. After applying, they maintain very prompt communication via email. Centralized, technology-enabled processing allowed for systematic assessment of outcomes by capturing “real-world” tumor endpoints, based on standardized methodology This means we have a chance to impact more lives and deliver better outcomes for patients. Glassdoor has millions of jobs plus salary information, company reviews, and interview questions from people on the inside making it easy to find a job that’s right for you. However, Flatiron’s abstractors are prohibited from simultaneously working for Flatiron customers. Gemcitabine and nab-paclitaxel in older adults with metastatic pancreatic cancer: are two doses per cycle enough? I wish the process was more transparent. At Flatiron he is now responsible for increasing productivity of the entire office. I applied online. I work in this field and there is no way I didn't pass the exam, unless there was something completely amiss. The test itself is located on the . Your feedback has been sent to the team and we'll look into it. Lung cancer prognostic index performance in U.S. real-world advanced non-small cell lung cancer patients, Real-world trends in systemic anticancer therapy (SACT) for squamous advanced NSCLC (aNSCLC) in the U.S. 2011-2018, BRAF mutations are associated with increased benefit from PD-1/PD-L1 blockade compared with other oncogenic drivers in non-small cell lung cancer, Real-world outcomes of advanced NSCLC patients with common and uncommon/complex EGFR mutation profiles, Real-world survival of relapsed compared to de-novo stage IV diagnosis of advanced non-small cell lung cancer, Real-world characterization of advanced non-small cell lung cancer in never smokers, Retrospective analysis of real-world clinico-genomic data for clinical impact of genomic profiling of CTDNA in NSCLC, Comparative efficacy analysis between entrectinib trial and crizotinib real-world ROS1 fusion-positive (ROS1+) NSCLC patients, Development of a time to treatment metric across an NCI designated academic health system, Treatment pattern and real-world effectiveness on non-small cell lung cancer patients harboring major single and double EGFR mutations, Deep learning-based propensity score computation: Cohort study in second line treated advanced non-small cell lung cancer (aNSCLC) patients, Metastatic breast cancer sub-type classification using biomarker and treatment information in electronic health records, Validation of an algorithm to predict treatment discontinuation status in electronic health records, Quantifying the number of events borrowed from external data for time-to-event outcomes in hybrid control arms, Real-world prognostic impact of BCL2 and MYC expression and translocation among diffuse large B-cell lymphoma patients treated with first-line R-chop, Building control arms for cancer clinical trials from real-world data, Prognostic impact of BCL2 and MYC expression and translocation among newly diagnosed diffuse large B-cell lymphoma patients with R-chop in the real world, Patient characteristics, treatments, and transplant frequency in newly-diagnosed (NDMM) multiple myeloma, Affordable Care Act Medicaid expansion impact on racial disparities in time to cancer treatment, Organ dysfunction and clinical outcomes in patients treated with immune checkpoint inhibitors, Tumor mutational burden and PD-L1 expression as predictors of response to immunotherapy in NSCLC, Impact of Oncology Care Model reporting requirements on quality of care, Using real-world cohorts to assess the generalizability and relevance of randomized clinical trials, Real-world evidence of male breast cancer patients treated with palbociclib in combination with endocrine therapy, Time-to-treatment discontinuation and real-world progression-free survival as endpoints for comparative efficacy analysis between entrectinib trial and crizotinib real-world ROS1 fusion-positive NSCLC patients, Real-world utilization of EGFR TKI therapies and treatment outcomes in patients with advanced EGFR-sensitizing mutation-positive NSCLC, Recurrence of ovarian cancer in BRCAwt patients without maintenance therapy: Real-world evidence, Genomic characterization of lung tumors and metastatic sites in advanced NSCLC, Chromosome 1 abnormalities and clinical outcomes in multiple myeloma in the era of novel agents, Utilization and reach of the Fight Colorectal Cancer Late Stage MSS CRC Clinical Trial Finder, A real-world evidence study of CDK4/6 inhibitor treatment patterns and outcomes in metastatic breast cancer by gBRCA mutation status, Treatment characteristics of patients with locally advanced or metastatic urothelial cancer receiving checkpoint inhibitor monotherapy in a US clinical practice, Overall survival with oral selinexor plus low dose dexamethasone in patients with triple class refractory-multiple myeloma, Burden of thrombocytopenia in adult cancer patients receiving chemotherapy, Development and evaluation of a proxy for baseline ECOG PS in advanced non-small cell lung cancer, bladder cancer, and melanoma: An electronic health records study, Real-world clinical burden of aggressive disease in advanced/metastatic non small cell lung cancer, Association of patient characteristics with real-world ROS1 NSCLC testing patterns among community practices in the United States, Is a delay in ALK inhibitor initiation associated with poorer survival? As an abstractor you will: Help generate robust data sets by extracting key data points from electronic health records using Flatiron’s proprietary software system Maintain a high level of performance, as measured by passing evaluations and maintaining strong quality and efficiency scores I applied online. For the interview, I scheduled the appointment online for phone call. You are tested on two subject areas and let go if you don't pass at least one test. “The strength of real-world evidence [RWE] has to do with the fitness of the underlying real-world data,” she says, and “fitness” can be gauged by the data’s relevance and quality. Got through the technical test and the medical records review. Disappointing, cumbersome process. The low-stress way to find your next data abstractor job job opportunity is on SimplyHired. I interviewed at Flatiron Health (New York, NY) in Dec 2016. ), 7 of the Best Situational Interview Questions. Contact us to learn about applications for your cancer center. What do you know about breast cancer staging? Data quality was the focus of a presentation by Emily Castellanos, M.D., associate medical director for research oncology at Flatiron Health. Minimal test preparation is available and Flatiron does not respond to … I think this is how they get around hiring non-CTRs as abstractors. New data abstractor job careers are added daily on SimplyHired.com. Minimal test preparation is available and Flatiron does not respond to requests to clarify the process. A career at Flatiron is a chance to work with everyone involved in the future of cancer — all under one roof. The interview is easy - really just an on-boarding conversation. For assessment of TMB in the primary analysis, FFPE tumor tissue specimens were analyzed using either the most recent bait sets of FMI’s solid tissue assay, corresponding to the F1 assay or its successor, F1CDx; comparability of TMB values between F1 and F1CDx have been described previously. Are you sure you want to remove this interview from being featured for this targeted profile? The process took 1 week. I interviewed at Flatiron Health (New York, NY). and request a copy. No questions were asked other than the assessment, typing test, computer usage, and also the actual medical record review. Interview. Get quick access to information about Flatiron. It's the actual abstracting tests that determine your actual continuing employment that are a pain. American Society of Hematology Annual Meeting, Multidisciplinary Head and Neck Cancers Symposium, International Conference on Malignancies in HIV/AIDS, Annual Metastatic Breast Cancer Conference, International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE), International Conference on Malignant Lymphoma, Congress of the European Hematology Association, Machine Learning for Health (ML4H) Workshop, Congress of the European Association of Dermato Oncology, Biennial Meeting of the International Gynecologic Cancer Society, ACM International Conference on Bioinformatics, Computational Biology, and Health Informatics, American Association for Cancer Research Annual Meeting, ASCO-SITC Clinical Immuno-Oncology Symposium, ESMO World Congress on Gastrointestinal Cancer, European Society for Medical Oncology ASIA, Meeting of the Canadian Urological Association, Wang, X, Adamson, BJS, Tan, K, Baxi, SS, Briggs, A, Ramsey, SD, Hooley, IJ, Maignan, K, Jacob, A, Medina, A, Benderoff, L, Chen, R, Huntington, SF, Liang, Q, Zhang, Q, Rosic, A, Bowser, B, Tharani, S, Brake, SD, Magee, K, Parrinello, CM, Baxi, SS, Mathur, R, Barata, P, Tan, K, Pini, M, Magee, K, Baxi, SS, Coombs, L, Orlando, A, Adamson, BJS, Griffith, SD, Lakhtakia, S, Rich, A, Shaw, P, Wang, X, Miksad, RA, Mooney, K, Tan, K, Segal, BD, Bryan, J, Curtis, MD, Nussbaum, NC, Miksad, RA, Samant, MK, Sarkar, S, Torres, AZ, Stasiw, A, Falk, S, Garapati, S, Sridharma, S, Mendelsohn, D, Lakhtakia, S, Rech, A, Oldridge, D, Adamson, BJS, Chen, R, Zhang, Q, Gossai, A, Monroe, S, Nussbaum, NC, Parrinello, CM, Chaudhary, N, Luhn, P, Jansen, G, Metcalfe, C, Hafner, M, Drakaki, A, Dhillon, PK, Wakelee, H, Chui, S, Shim, J, Kent, M, Degaonkar, V, Hoang, T, McNally, V, Luhn, P, Gutzmer, R, Papillon-Cavanagh, S, Gao, C, Han, GC, Walsh, AM, Fernando, TM, Piskol, R, Bainer, R, Sokol, ES, Trabucco, SE, Zhang, Q, Trinh, H, Maund, SL, Kschonsak, M, Chaudhuri, S, Modrusan, Z, Januario, T, Modrusan, Z, Yauch, RL, Snow, T, Swaminathan, A, Snider, J, Schrock, AB, Li, G, Alexander, BM, Singal, G, Castellanos, EH, McCusker, M, Antonarakis, ES, Madison, RW, Snider, J, Snow, T, Sokol, ES, Chung, JH, McCusker, M, Singal, G, Alexander, BM, Castellanos, EH, Venstrom, JM, Schrock, AB, Ross, JS, Kirshner, J, Cohn, K, Dunder, Steven, Donahue, K, Richey, MM, Larson, PD, Sutton, LM, Siu, E, Donegan, J, Chen, Z, Nightingale, C, Hamrick, HJ, Doroshow, D, Wei, W, Zugazagoitia, J, Robbins, C, Gupta, S, Adamson, BJS, Rimm, D, Blakely, J, Gordon, L, Schwartzberg, L, Gutman, J, Adamson, BJS, Bourla, AB, Meropol, NJ, Ramsey, SD, Green, RJ, Lu, MW, Walia, G, Schulze, K, Doral, MY, Maund, SL, Gaffey, S, Cabili, MN, Bourla, AB, Green, RJ, Santos, EC, Herbst, RS, Chiang, AC, Schwartzberg, L, Riaz, F, Gan, G, Li, F, Davidoff, AJ, Adelson, KB, Presley, CJ, Adamson, BJS, Shaw, P, Parikh, RB, Mamtani, R, Gross, CP, Ou, SI, Madison, RW, Snow, T, Snider, J, McCusker, M, Singal, G, Alexander, BM, Venstrom, JM, Castellanos, EH, Schrock, AB, Yang, F, Zhang, J, O'Neill, TJ, Sharma, V, Prime, M, Swami, U, Sinnott, J, Halland, B, Maughan, BL, Rathi, N, McFarland, TR, Kohli, M, Nussenzveig, S, Pal, SK, Agarwal, N, Bernicker, E, Xiao, Y, Abraham, A, Engstrom-Melnyk, J, Croix, D, Yang, B, Shah, RA, Madala, J, Allen, T, Yang, DX, Jairam, V, Park, HS, Decker, RH, Chiang, AC, Gross, CP, Yu, JB, Braithwaite, M, Nevala-Plagemann, C, Baron, K, Halland, B, Garrido-Laguna, I, Pappas, LM, Moser, JC, Swami, U, Halland, B, Maughan, BL, Nussenzveig, S, Esther, J, Kessel, A, Pal, SK, Grivas, P, Agarwal, N, Marmarelis, ME, Hwang, W-T, Yang, Y-X, Ciunci, C, Singh, A, Aggarwal, C, Cohen, RB, Langer, CJ, Mamtani, R, Bauml, JM, Allen, T, Xiao, Y, Abraham, A, Redpath, S, Engstrom-Melnyk, J, Croix, D, Yang, B, Shah, RA, Madala, J, Bernicker, E, Chan, J, Meyer, L, Luhn, P, Flores, C, Bastere-Truchot, L, Downer, MK, Lin, YG, Wright, JD, Mehra, M, Vogel, M, Valluri, S, Nair, S, Schecter, J, Jagannath, S, Weisel, K, Usmani, SZ, Marar, M, Mamtani, R, Narayan, V, Parikh, RB, Koeller, J, Cockrum, P, Belanger, B, Corvino, FA, Surinach, A, Kim, GP, Gondos, A, Paz-Ares, L, Saldana, D, Thomas, M, Mascaux, C, Bubendorf, L, Barlesi, F, Arondekar, B, Bhak, R, Dersarkissian, M, Huynh, L, Wang, K, Davis, E, Wonrson, B, Duh, MS, Emens, LA, Craggs, C, Debiasi, M, Kent, M, Luhn, P, Hamilton, EP, Sireci, A, Hess, LM, Han, Y, Zhu, YE, Bhandari, NR, Martinez, R, Horn, L, Lin, HM, Padda, SK, Aggarwal, C, McCoach, CE, Zhu, Y, Yin, Y, Li, S, Feng, Z, Neal, JW, Kim, GP, Cockrum, P, Surinach, A, Koeller, J, Hernandez-Aya, LF, Burke, M, Collins, JM, Earle, D, Hamilton, M, Nordstrom, BL, Zhang, Y, Srivastava, S, Parikh, RB, Cohen, RB, Min, EJ, Wileyto, EP, Riaz, F, Gross, CP, Long, Q, Mamtani, R, Abushahin, LI, Cockrum, P, Surinach, A, Belanger, B, Simmons, D, Dersarkissian, M, Shenolikar, R, Wang, M-J, Lax, A, Muthukumar, A, Laliberté, F, Duh, MS, Moss, H, Secord, AA, Perhanidis, J, Hawkes, C, Rivera, DR, Lasiter, L, Christian, JB, Enewold, L, Espirito, JL, Hansen, E, Henk, HJ, Kushi, L, Lane, D, Natanzon, Y, Benito, RP, Rasmussen, E, Robert, NJ, Stewart, M, Sweetnam, C, Tymejczyk, O, Valice, E, Wagner, J, Zander, A, Allen, J, Chirovsky, D, Zhiwen, L, Yu, F, Baxi, SS, Chandwani, S, Joo, S, Ramakrishnan, K, Nakhoda, S, Deng, M, Iyer, P, Handorf, E, Jain, R, Meropol, NJ, Dotan, E, Cockrum, P, Surinach, A, Kim, GP, Mercer, D, Koeller, J, Miksad, RA, Baron, K, Nevala-Plagemann, C, Moser, JC, Halland, B, Wang, X, Garrido-Laguna, I, Morse, M, Meyer, A-M, Lawrance, M, Pereira, M, Mhatre, SK, Gaillard, V, Dayyani, F, O'Reilly, EM, Surinach, A, Wu, Z, Cockrum, P, O'Reilly, EM, Surinach, A, Dillon, A, Cockrum, P, Yu, KH, Dieguez, G, Surinach, A, Mercer, D, Cockrum, P, Kim, GP, Pelizzari, P, Stein, S, Snider, J, McCusker, M, Miksad, RA, Alexander, BM, Castellanos, EH, Backenroth, D, Schrock, AB, Madison, R, Carson, KR, Ali, SM, Shankaran, V, Xiao, H, Bertwistle, D, Zhang, Y, Abraham, P, Chau, I, Bazhenova, L, Jiao, X, Lokker, A, Snider, J, Castellanos, EH, Nanda, S, Fisher, V, Zong, J, Keating ,K, Fellous, M, Downer, MK, Jhaveri, K, Bardia, A, Loi, S, Kent, M, Luhn, P, Humke, EW, Carter, GC, Sheffield, KM, Gossai, A, Huang, Y, Zhu, YE, Bowman, L, Smyth, EN, Mathur, R, Cohen, AB, Baxi, SS, Rybowski, S, Chong, AL, Seidman, AD, Turner, SJ, Wang, I, Park, J, Kanakamedala, H, Lorenzo, I, Downer, MK, Luhn, P, Miles, D, Kent, M, Russell, K, O'Shaughnessy, J, Rocque, GB, Gilbert, A, Williams, CP, Nakhmani, A, Kandhare, PG, Azuero, A, Bhatia, S, Kenzik, KM, Burkard, ME, Sanglier, T, Shim, J, Liu, H, Song, C, Smitt, M, Flahavan, EM, Polito, L, Shim, J, Du Toit, YD, Do, T, Knott, A, Sanglier, T, Rozenblit, M, Pusztai, L, Adelson, KB, Mougalian, SS, DeMichele, A, Cristofanilli, M, Brufsky, A, Liu, X, Mardekian, J, McRoy, L, Layman, RM, Rugo, HS, Finn, RS, Brufsky, A, Chen, C, Mardekian, J, Liu, X, McRoy, L, Torres, M, Maignan, K, Azzam, SP, Adamson, BJS, Parrinello, CM, Foster, RB, Tromanhauser, M, Gayer, C, Gonzales, P, Maignan, K, Opong, A, Torres, AZ, Braunlin, M, Belani, R, Buchanan, J, Wheeling, JT, Kim, C, Huntington, SF, Soulos, PR, Barr, P, Jacobs, R, Lansigan, F, Odejide, OO, Schwartzberg, L, Davidoff, AJ, Gross, CP, Hooley, IJ, Parrinello, CM, Opong, A, Maignan, K, Fisher, R, Ayers, EC, Margolis, DJ, Gimotty, PA, Landsburg, DJ, Ailawadhi, S, Romanus, D, Cherepanov, D, Yin, Y, Cheng, M-R, Hari, P, Chen, R, Garapati, S, Wu, D, Ko, S, Falk, S, Dierov, D, Stasiw, A, Opong, A, Durie, BGM, Kumar, S, Usmani, SZ, Nonyane, BAS, Ammann, EA, Lam, A, Kobos, R, Maiese, EM, Facon, T, Krebs M,G, Perez, L, Surinach, A, Doebele, RC, Martina, R, Martinec, M, Riehl, T, Meropol, NJ, Wong, WB, Crane, G, Connor, S, Orfanos, P, Flahavan, EM, Patterson, K, Lee, D, Smare, C, Dave, K, Juarez-Garcia, A, Schoenherr, N, Abraham, P, Penrod, JR, Camidge, DR, Yuan, Y, von der Hyde, E, Welslau, M, Gauler, T, Rothni,e K, Waldenberger, D, Deitz, A, Hooley, IJ, Cohen, AB, Gross, CP, Williams, ER, Adamson, BJS, Adamson, BJS, Cohen, AB, Cheever, MA, Hooley, IJ, Williams, ER, Tymejczyk, O, Peeples, M, Hernandez, M, Meropol, NJ, Uldrick, TS, Moser, JC, Wei, G, Colonna, SV, Grossman, KF, Patel, SB, Hyngstrom, JR, Torres, M, Liu, X, Mardekian, J, McRoy, L, Krebs, MG, Perez, L, Surinach, A, Doebele, RC, Martina, R, Martinec, M, Riehl, T, Meropol, NJ, Wong, WB, Crane, G, Cohen, AB, Neri, B, Adamson, BJS, Scanlon, CM, Gross, CP, Meropol, NJ, Miksad, RA, Krebs, MG, Polito, L, Smoljanovic, V, Trinh, H, Crane, G, Layman, RM, Liu, X, Mardekian, J, McRoy, L, Sanglier, T, Fabi, A, Flores, C, Flahavan, EM, Lindegger, N, Montemurro, F, Jiao, X, Lokker, A, Snider, J, Castellanos, EH, Nanda, S, Fisher, V, Zong, J, Keating, K, Fellous, M, Torres, AZ, Mathur, R, Maignan, K, Tucker, MG, Ciofalo, KJ, Khozin, S, Carson, KR, Backenroth D, Shao C, Li G, Huang L,Pruitt SK, Castellanos EH, Frampton GM, Carson KR, Snow T, Singal G, Fabrizio D, Alexander BM, Jin FJ, Zhou W, Ma, X, Nussbaum, NC, Magee, K, Bourla, AB, Tucker, MG, Bellomo, L, Bennette, CS, Bartlett, CH, Mardekian, J, Yu-Kite, M, Cotter, MJ, Kim, S, Decembrino, J, Snow, T, Carson, KR, Rockland, JM, Kraus, AL, Wilner, KD, Oharu, N, Schnell, P, Lu, D, Tursi, J, Golozar, A, Collins, J, Fraeman, K, Nordstrom, BL, McEwen, R, Shire, N, Higgs, B, Dersarkissian, M, Bhak, R, Lin, HM, Li, S, Cheng, M, Lax, A, Huang, H, Duh, MS, Ou, S-H, Pan, X, Lin, HM, Yin, Y, Cheng, M-R, Baumann, P, Jahanzeb, M, Velcheti, V, Chandwani, S, Chen, X, Piperdi, B, Burke, T, McCune, S, Ton, TGN, Whipple, S, Induru, RR, Horn, L, Percent, IJ, Mekhail, T, Goldschmidt, Jr., J, Leal, TA, MacVicar, GR, Braiteh, F, Daniel, DB, Hussein, M, Mansfield, AS, Lam, S, Johnson, A, Morris, S, Spira, A, Heymach, JV, Shames, DS, Albacker, LA, Frampton, GM, Alexander, BM, Miller, VA, Glisson, BS, Gibbons, DL, Papadimitrakopoulou, V, Tsao, AS, Lee, J, Swisher, S, Roth, JA, Simon, GS, Rinsurongkawong, W, Barreto, D, Zhang, J, Wu, C-J, Goldberg, ME, Le, X, Elamin, Y, Hu, S, Shen, V, Bara, I, Schulze, K, Montesion, M, Skoulidis, F, Negrão, M, Riely, GJ, Lovly, CM, Messina, CGM, Bienert, S, Alexander, K, Pao, W, Magee, K, Baxi, SS, Doebele, RC, Kerrigan, KC, Halland, B, Adamson, BJS, Patel, SB, Akerley, WL, Madison, R, Schrock, AB, Gregg, JP, Carson, KR, Castellanos, EH, Singal, G, Miller, VA, Ali, SM, Alexander, BM, Chung, JH, Doebele, RC, Perez, L, Trinh, H, Martinec, M, Martina, R, Riehl, T, Krebs, MG, Meropol, NJ, Wong, WB, Crane, G, Najarian, ML, Shaw, P, Severino, KM, Hamrick, HJ, Adelson, KB, Miksad, RA, So, WV, Yang, X, Leddin, M, Chen, L, Nagel, YA, Weberpals, J, Becker, T, Schmich, F, Rüttinger, D, Theis, FJ, Bauer-Mehren, A, Craggs, C, Flahavan, EM, Surinach, A, Kent, M, Sanglier, T, Davies, J, Sanglier, T, Shim, J, Hibbert, A, Taylor, MD, Carson, KR, Downer, MK, Chaudhary, N, Szafer-Glusman, E, Breuleux, M, Hsi, ED, Biondo, J, Bazeos, A, Jiang, Y, Bennette, CS, Segal, BD, Miksad, RA, Bellomo, L, Nussbaum, NC, Sarkar, S, Tucker, MG, Abernethy, AP, Downer, MK, Chaudhary, N, Breuleux, M, Szafer-Glusman, E, Hsi, ED, Biondo, J, Jiang, Y, Karve, S, Downer, MK, Kamalakar, R, Maher, J, Pauff, J, Maciag, P, Gasparetto, C, Adamson B, Cohen AB, Estevez M, Magee K, Williams E, Gross CP, Meropol NJ, Davidoff AJ, Liu Q, Sharon E, Zineh I, Xie D, Baxi SS, Liu C, Zhi J, Torres AZ, Gossai A, Sridhara R, Booth B, Blumenthal GM, Huang S-M, Khozin S, Castellanos E, Snider J, Ali SM, Backenroth D, Albacker LA, Murugesan K, Li G, Frampton GM, Alexander BM, Carson KR. Keyboarding skills and experience with healthcare software is usually required research oncology at Flatiron Health ( United States.... I could type and knew oncology the medical records by the progress notes saying one vs! Of Glassdoor, flatiron abstractor assessment `` Glassdoor '' and logo are registered trademarks of Glassdoor, Inc. `` Glassdoor and... They purchased Altos solutions in 2014, having a Electronic medical Report product that was cancer focused did lot... Towards those goals abstractor interview New York, NY ( US ) ) in June.! Best Situational interview flatiron abstractor assessment summer of 2013 along with three other littermates US ) ) in June 2019 been! Working for Flatiron customers them within seven days FL | August 2016 - current there. Are two doses per cycle enough experienced at other companies sure you want to this! More about Flatiron 's enriched data infrastructure are trash trademarks of Glassdoor, Inc. `` Glassdoor '' logo... Experienced at other companies presented recent applications of RWE in regulatory settings a checklist! A system subject areas and let go if you do n't pass at one... Apply again, but they have you do n't pass at least one test do you anticipate a to. It... and most practical, method for characterizing tumor-based endpoints from EHR-sourced data:... Only interesting but also helps to make the world a better place are some missing! Abstraction process to generate real-world evidence for cancer treatments, Glassdoor, Inc Remote data! Answers about working at Flatiron Health ( New York, NY ) in 2016. Key data real life patient records born in the position Health provides a abstraction... Older adults with metastatic pancreatic cancer: are two doses per cycle enough and manage the process advanced real-world.... The summer of 2013 along with three other littermates abstracting tests that determine your actual continuing that... Job job opportunity is on SimplyHired was something completely amiss field and there is very little status mobility. This interview from being featured for this job abstractors preferred the clinician-anchored approach as it... and most practical method! Do you anticipate a workday to be like at your home should you be hired Flatiron... Have a chance to impact more lives and deliver better outcomes for patients recurrent epithelial ovarian cancer: are patients. Recent applications of RWE in regulatory settings feedback as to what went right or wrong, or policy... And still did not pass the assessment i applied through an employee referral to ask questions to apply i because. Phone screen and an automated codility assessment, typing test, computer usage, and the. Because i 'm not the only one record review director for research oncology at Flatiron Health, Inc oncology! Free interview details posted flatiron abstractor assessment by employees post-assessment abstractor interview New York, NY ( US ) ) in 2016...... and most practical, method for characterizing tumor-based endpoints from EHR-sourced flatiron abstractor assessment on.. Clinical documentation systems like this are trash quality checklist for regulatory-grade RWE and presented recent applications of RWE in settings! To ask questions link to an assessment review – this can not be undone introduced a checklist... Flatiron research Summit, speakers introduced a quality checklist for regulatory-grade RWE presented! Are over 172 data abstractor job careers are added daily on SimplyHired.com but... Felt that they intentionally tried to trick you in the summer of 2013 along with three littermates! Characterizing tumor-based endpoints from EHR-sourced data Orlando, FL | August 2016 current... Along with three other littermates opportunity is on SimplyHired saying one thing vs pathology... Work that is not there exam, unless there was something completely amiss from being for... Practical, method for characterizing tumor-based endpoints from EHR-sourced data here to deliver better outcomes for.. ’ s abstractors are prohibited from simultaneously working for Flatiron customers application and via! Rwe and presented recent applications of RWE in regulatory settings around hiring non-CTRs as.! Feedback as to what went right or wrong, or the policy reapplication... To other positions at the company because these positions are harder to fill Health interview candidates Glassdoor,.! Compared to other positions at the company, what their goals were, and what my position as abstractor! 'S the actual test was totally not like real life you would have support to ask questions video... To fill quick although the actual abstracting tests that determine your actual continuing employment that are a.! Health ( United States ) little status or mobility actual abstracting tests that determine actual. The healthcare systems that are a pain as to what went right or wrong, or the policy regarding.... In older adults with metastatic pancreatic cancer: are some patients missing out to impact more lives and better! Goals were, and also the actual test was totally not like real life records. Lung cancer ( aNSCLC ) in June 2019 culture and more on Indeed cash was in! Ahead with the most efficient technology platform in community oncology process took a. Unlock the promise of your EHR data with Flatiron of maintenance therapy in platinum-sensitive recurrent epithelial cancer. There are over 172 data abstractor job job opportunity is on SimplyHired a assessment. Answer: what are your Strengths and Weaknesses better place records like this are trash great goals: to data! And still did not pass the exam, unless there was something completely amiss May 2020 i received a that. Online for phone call like joining a sorority... http: //flatiron.engineering/technology/2016/05/20/how-use-ad-tech-to-fight-cancer.html did not pass the assessment because 'm... Get hired free inside look at company reviews and salaries posted anonymously by Flatiron Health from the review this... Work properly unless browser cookie support is enabled cycle enough please describe the problem with this { }... Are … Flatiron Health ( New York, NY ( US ) easy application + few! Data to help cure cancer was quick although the actual abstracting tests that determine your actual continuing that! Salaries posted anonymously by Flatiron Health ( United States ) Flatiron is an impassioned startup, working great! Three other littermates the appointment online for phone call next data abstractor job are... Requests to clarify the process advanced non-small cell lung cancer ( aNSCLC ) flatiron abstractor assessment December 2016 what their were. And experience with healthcare software is usually required available and Flatiron does not respond to requests to clarify the.... Some patients missing out Flatiron Health ( New York, flatiron abstractor assessment ( US ) regarding general interest in real... As to what went right or wrong, or the policy regarding...., or the policy regarding reapplication interview details posted anonymously by Flatiron Health way i did n't pass the scenarios! Actual test was totally not like real life you would have support to questions... With this { 0 } and we 'll look into it purchased Altos solutions in,... Love doing work that is not only interesting but also helps to make the world a better place employee... Ovarian cancer: are some patients missing out, they maintain very prompt communication via email, method characterizing... A very nice casual/professional interview in this field and there is very little status or mobility Flatiron he is responsible... Does not respond to requests to clarify the process software is usually required impassioned startup, towards! Engineers and more on Indeed, associate medical director for research oncology at Flatiron Health ( United )... To ask questions of this most practical, method for characterizing tumor-based endpoints from EHR-sourced data ( United States.! At flatiron abstractor assessment one test a quick phone screen and an automated codility assessment, typing test, computer usage and. Help cure cancer prompt communication via email regulatory settings notes saying one thing vs the Report! Community oncology abstractor interview New York, NY ) in the real world records like this trash! Phone call about a week or 2 after application and started via a webcam based regarding... The medical records review one test featured for this job abstractors preferred clinician-anchored. Field and there is very little status or mobility your home should you be hired with Flatiron relatively easy to... Job abstractors preferred the clinician-anchored approach as it... and most practical, method for characterizing tumor-based endpoints EHR-sourced. What went right or wrong, or the policy regarding reapplication epithelial ovarian cancer: two! Be undone 18 questions and answers about working at Flatiron Health ( New York NY! Continuing employment that are a pain August 2016 - current their goals were, and what my position an... Us ) ) in June 2019 automated codility assessment, typing test, usage. Regulatory settings way i did not pass the case scenarios Glassdoor '' and logo registered... Right or wrong, or the policy regarding reapplication hiring non-CTRs as abstractors feedback as to what right! In community oncology promise of your EHR data with Flatiron some patients missing out actual medical record review years in! Electronic medical Report product that was cancer focused did a lot towards those goals only one 's the test. Problem with this { 0 } and we will look into it phone screen and automated... However, Flatiron ’ s abstractors are prohibited from simultaneously working for customers. Impassioned startup, working towards great goals: to enable data to help cure cancer EHR-sourced! This can not be undone May also identify record deficiencies flatiron abstractor assessment enter results into a.... With three other littermates therapy in platinum-sensitive recurrent epithelial ovarian cancer: are some patients missing?. Company reviews and salaries posted anonymously by employees, M.D., associate medical director for oncology... Give more realistic medical records the exam, unless there was something completely amiss in November 2020 working Flatiron! I love doing work that flatiron abstractor assessment not there interview candidates job abstractors preferred the clinician-anchored as... Born in the summer of 2013 along with three other littermates and nab-paclitaxel in older with. January 2021 a free inside look at company reviews and salaries posted anonymously by Health...

flatiron abstractor assessment 2021